In humans, pioglitazone treatment enhances insulin-stimulated myocardial glucose uptake as measured through 18FDG PET across the whole spectrum of glucose tolerance [32, 41, 75], including T2D with coronary artery disease [76]. This evidence concerns the gene INS and coronary artery disorder.